Outcomes of Glaucoma Drainage Device Surgery in Eyes with Treated Uveal Melanoma

Overview

Journal Ocul Oncol Pathol

Date 2019 Jan 25

PMID 30675473

Citations 1

Authors

Nima Fatehi

Tara A McCannel

JoAnn Giaconi

Joseph Caprioli

Simon K Law

Kouros Nouri-Mahdavi

Affiliations

Soon will be listed here.

Abstract

Aim: We report patient safety and intraocular pressure (IOP) control after placement of a glaucoma drainage device (GDD) in eyes with a history of treated malignant uveal melanoma.

Methods: A retrospective review of the records of patients with uveal melanoma was performed. Outcomes were local tumor recurrence, rate of metastases, and to-nometric success, based on survival curves, defined as IOP < 21 mm Hg.

Results: Eleven eyes with choroidal melanoma, 4 with iris melanoma, and 1 with ciliary body melanoma were followed for a median (interquartile range) of 2.1 (1.1-3.2) years. Two subjects developed liver metastases; one had monosomy 3 and tumor gene expression profile class 2. The other case with ciliary body melanoma was negative for monosomy 3. There were no cases of local treatment failure. Mean preoperative IOP decreased from 30.5 ± 7.7 to 15.9 ± 8.1 mm Hg at 1 year after surgery (1-year success rate 80%).

Conclusions: Our case series with a median follow-up of 2 years shows that placing a GDD in patients with treated uveal melanoma does not expose patients to greater risk of local or extraocular recurrence. A larger series and longer follow-up time are required to fully evaluate the safety of GDDs in this clinical scenario.

Citing Articles

Treatment of uncontrolled intraocular pressure secondary to uveal melanoma status post plaque radiotherapy with ab interno XEN gel stent implantation.

Harvey B, John F, Leal C, Firestone B Am J Ophthalmol Case Rep. 2022; 27:101610.

PMID: 35756838 PMC: 9214786. DOI: 10.1016/j.ajoc.2022.101610.

References

Shields C, Shields J, Materin M, Gershenbaum E, Singh A, Smith A . Iris melanoma: risk factors for metastasis in 169 consecutive patients. Ophthalmology. 2001; 108(1):172-8. DOI: 10.1016/s0161-6420(00)00449-8. View

Shields C, Materin M, Shields J, Gershenbaum E, Singh A, Smith A . Factors associated with elevated intraocular pressure in eyes with iris melanoma. Br J Ophthalmol. 2001; 85(6):666-9. PMC: 1724017. DOI: 10.1136/bjo.85.6.666. View

Singh A, Shields C, Shields J . Prognostic factors in uveal melanoma. Melanoma Res. 2001; 11(3):255-63. DOI: 10.1097/00008390-200106000-00007. View

Egger E, Schalenbourg A, Zografos L, BERCHER L, Boehringer T, Chamot L . Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys. 2001; 51(1):138-47. DOI: 10.1016/s0360-3016(01)01560-7. View

Girkin C, Goldberg I, Mansberger S, Shields J, Shields C . Management of iris melanoma with secondary glaucoma. J Glaucoma. 2002; 11(1):71-4. DOI: 10.1097/00061198-200202000-00013. View

Gragoudas E, Li W, Goitein M, Lane A, Munzenrider J, Egan K . Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol. 2002; 120(12):1665-71. DOI: 10.1001/archopht.120.12.1665. View

Egger E, Zografos L, Schalenbourg A, Beati D, Bohringer T, Chamot L . Eye retention after proton beam radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys. 2003; 55(4):867-80. DOI: 10.1016/s0360-3016(02)04200-1. View

Singh A, Topham A . Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003; 110(5):962-5. DOI: 10.1016/S0161-6420(03)00077-0. View

JENSEN O . MALIGNANT MELANOMAS OF THE UVEA IN DENMARK 1943-1952. A CLINICAL, HISTOPATHOLOGICAL, AND PROGNOSTIC STUDY. Acta Ophthalmol (Copenh). 1963; 43:SUPPL 75:1-220. View

10.

Pasternak S, Erwenne C, Nicolela M . Subconjunctival spread of ciliary body melanoma after glaucoma filtering surgery: a clinicopathological case report. Can J Ophthalmol. 2005; 40(1):69-71. DOI: 10.1016/S0008-4182(05)80120-6. View

11.

Damato B, Kacperek A, Chopra M, Sheen M, Campbell I, Errington R . Proton beam radiotherapy of iris melanoma. Int J Radiat Oncol Biol Phys. 2005; 63(1):109-15. DOI: 10.1016/j.ijrobp.2005.01.050. View

12.

Wanner J, Pasquale L . Glaucomas secondary to intraocular melanomas. Semin Ophthalmol. 2006; 21(3):181-9. DOI: 10.1080/08820530500351744. View

13.

Gedde S, Herndon L, Brandt J, Budenz D, Feuer W, Schiffman J . Surgical complications in the Tube Versus Trabeculectomy Study during the first year of follow-up. Am J Ophthalmol. 2006; 143(1):23-31. DOI: 10.1016/j.ajo.2006.07.022. View

14.

Young T, Rao N, Glasgow B, Moral J, Straatsma B . Fluorescent in situ hybridization for monosomy 3 via 30-gauge fine-needle aspiration biopsy of choroidal melanoma in vivo. Ophthalmology. 2006; 114(1):142-6. DOI: 10.1016/j.ophtha.2006.06.040. View

15.

. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 2006; 124(12):1684-93. DOI: 10.1001/archopht.124.12.1684. View

16.

Durkin S, Roos D, Higgs B, Casson R, Selva D . Ophthalmic and adnexal complications of radiotherapy. Acta Ophthalmol Scand. 2007; 85(3):240-50. DOI: 10.1111/j.1600-0420.2006.00822.x. View

17.

Shields J, Shields C, Donoso L . Management of posterior uveal melanoma. Surv Ophthalmol. 1991; 36(3):161-95. DOI: 10.1016/0039-6257(91)90001-v. View

18.

Minckler D, Francis B, Hodapp E, Jampel H, Lin S, Samples J . Aqueous shunts in glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology. 2008; 115(6):1089-98. DOI: 10.1016/j.ophtha.2008.03.031. View

19.

Tay E, Cree I, Hungerford J, Franks W . Recurrence of treated ciliary body melanoma following trabeculectomy. Clin Exp Ophthalmol. 2009; 37(5):503-5. DOI: 10.1111/j.1442-9071.2009.02069.x. View

20.

Shields C, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally D . Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009; 127(8):989-98. DOI: 10.1001/archophthalmol.2009.208. View